These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11145005)

  • 1. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
    Růzicka E; Streitová H; Jech R; Kanovský P; Roth J; Rektorová I; Mecír P; Hortová H; Bares M; Hejduková B; Rektor I
    J Neural Transm (Vienna); 2000; 107(11):1297-306. PubMed ID: 11145005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
    Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open-Label Pilot Study.
    Khlebtovsky A; Steiner I; Treves T; Djaldetti R
    Clin Transl Sci; 2019 Nov; 12(6):586-590. PubMed ID: 31436382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG; Zapf A; Brunner E; Trenkwalder C
    Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease.
    Mostile G; Nicoletti A; Dibilio V; Luca A; Raciti L; Sciacca G; Cicero CE; Vasta R; Donzuso G; Contrafatto D; Zappia M
    Clin Neuropharmacol; 2017; 40(1):6-10. PubMed ID: 27879548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
    Metman LV; Del Dotto P; LePoole K; Konitsiotis S; Fang J; Chase TN
    Arch Neurol; 1999 Nov; 56(11):1383-6. PubMed ID: 10555659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor fluctuations in levodopa treatment: clinical pharmacology.
    Stocchi F; Bonamartini A; Vacca L; Ruggieri S
    Eur Neurol; 1996; 36 Suppl 1():38-42. PubMed ID: 8791020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations.
    Tsang KL; Ho SL; Lo SK
    Neurology; 2000 Jun; 54(12):2292-8. PubMed ID: 10881255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.